This article is more than 5 years old. Information may no longer be current.
IG-IMRT showed favorable outcomes in skull base chordoma, chondrosarcoma
Click Here to Manage Email Alerts
Patients with chordomas or chondrosarcomas of the skull base had favorable 5-year OS and local control after high-dose image-guided intensity-modulated radiation therapy, according to study results.
Arjun Sahgal, MD, of the department of radiation oncology at Sunnybrook Odette Cancer Centre in Toronto, and colleagues administered high-dose IG-IMRT to 42 consecutive patients with either skull base chordoma (n=24) or chondrosarcoma (n=18) who were treated between August 2001 and December 2012.
All patients initially received either biopsy (7%), subtotal resection (57%) or gross total resection (36%). Median IG-IMRT total doses were 70 Gy for the chondrosarcoma cohort and 76 Gy in the chordoma cohort. IG-IMRT doses were delivered with 2 Gy/fraction.
Median follow-up was 36 months in the chordoma cohort and 67 months in the chondrosarcoma cohort.
Five-year OS was 85.6% in the chordoma cohort and 87.8% in the chondrosarcoma cohort.
Local control rates were 65.3% in the chordoma cohort and 88.1% in the chondrosarcoma cohort.
Eight patients with chordomas progressed locally compared with two patients with chondrosarcomas. Both failures in the chondrosarcoma cohort were associated with grade 2 or 3 tumors, and none of the eight patients with grade 1 chondrosarcoma failed.
Eight patients experienced radiation-induced late effects, including a radiation-induced secondary malignancy that occurred 6.7 years after treatment.
“Gross total resection and age were predictors of local control in the chordoma and chondrosarcoma cohorts, respectively,” Sahgal and colleagues wrote. “Further follow-up is needed to confirm long-term efficacy.”
Disclosure: See the full study for a list of the researchers’ relevant financial disclosures.
Click Here to Manage Email Alerts